California, US residentsclick here.

The job details are as follows:

Who We Are

We are the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation. Our public benefit purpose is to provide a brighter future for patients through the development of novel pharmaceutical therapies; and technologies that expand the availability of transplantable organs.

United Therapeutics (Nasdaq: UTHR) seeks to travel down the corridors of indifference to develop treatments for rare, deadly diseases. We were founded in 1996 by a family seeking a cure for their daughter’s pulmonary arterial hypertension (PAH). Today, we have six FDA-approved therapies that treat PAH, pulmonary hypertension associated with interstitial lung disease (PH-ILD) and neuroblastoma, a rare pediatric cancer. Our near-term pipeline seeks to develop additional therapies for PAH and pulmonary fibrosis (PF).

The cure for end-stage life-threatening diseases like PAH, PH-ILD, PF, and many others is an organ transplant, but only a small percentage of donated organs are available to address the vast need. For this reason, we are working to create manufactured organs to address the shortage of kidneys, hearts, lungs, and livers available for transplant. We believe an unlimited supply of tolerable, transplantable organs will eliminate the transplant waiting list and cure end-stage organ diseases for which transplant is not currently an option.

Who You Are

You're a problem solver who thrives at the intersection of technology and business. You enjoy building relationships, navigating complex challenges, and leading solutions that drive meaningful outcomes. You can confidently manage multiple high-impact initiatives, work across diverse stakeholder groups, and translate business needs into technical solutions. Most importantly, you're energized by helping teams make better decisions through data and analytics.

The Senior Data Engineer will play a crucial role in designing, developing, and maintaining our data and analytics architecture, ensuring efficient data flow and management across the organization. This role requires a deep understanding of data engineering principles, advanced programming skills, and the ability to work collaboratively with cross-functional teams to deliver high-quality data solutions.

Design, build and optimize ETL/ELT pipelines using Databricks and Azure Data Factory to support enterprise data warehousing and analytics
Work with stakeholders to provide access and security controls
Support and maintain daily data processing operations, including monitoring, alerting, and issue resolution
Collaborate with analysts, data scientists, and other stakeholders to understand data requirements and deliver solutions
Provide technical guidance and mentorship to junior data engineers and other team members, including reviewing and validating work delivered by external consultants
Monitor and troubleshoot data systems (e.g., SQL Databases, Databricks) to ensure performance and reliability
Implement best practices for data management; lead initiatives to improve practices, tools, and processes
Participate in code reviews, design discussions, and contribute to technical documentation
Provide consultation and leadership around business intelligence and analytics platforms

Minimum Requirements

5+ years of experience building and maintaining business-critical EDW and pipelines with a Bachelor’s Degree
3+ years of experience with data architecting and engineering in a role with a proven track record of delivering complex data solutions
3+ years of Tier 1 SaaS integration work (e.g. Salesforce) or equivalent
3+ years of experience working with AppDev and/or BI/AI team members
Advanced SQL Skills, including complex query writing, performance tuning/optimization, and stored procedure development
Hands-on, production-level experience with Azure Databricks, including Spark based data processing, notebooks, and Delta Lake
Hands-on, production-level experience with Azure Data Factory, building, orchestrating, and monitoring ETL/ELT pipelines
Hands-on experience with cloud platforms – Azure preferred
Proficiency in programming languages such as Python
Understanding of data warehousing concepts
Highly proficient and excels in working with custom applications and complicated data platforms – beyond off-the-shelf systems
Excellent problem solving and analytical skills with strong communication and interpersonal skills
Ability to manage multiple priorities and projects simultaneously and effectively in, or outside, of a team
Demonstrated experience delivering data processing reliability
Proficiency working with business intelligence and analytical platforms

Job Location

This position will be located in the RTP, NC office of United Therapeutics. Currently this job is a hybrid role requiring at least three days per week in the office. In office requirements could increase based on business needs.

At United Therapeutics, our mission and vision are one. We use our enthusiasm, creativity, and persistence to innovate for the unmet medical needs of our patients and to benefit our other stakeholders. We are bold and unconventional. We have fun, we do good.

Eligible employees may participate in the Company’s comprehensive benefits suite of programs, including medical / dental / vision / prescription coverage, employee wellness resources, savings plans (401k and ESPP), paid time off & paid parental leave benefits, disability benefits, and more. For additional information on Company benefits, please visit https://www.unither.com/careers/benefits-and-amenities

United Therapeutics Corporation is an Equal Opportunity Employer, including veterans and individuals with disabilities.

About the company

United Therapeutics develops therapies for life-threatening diseases, with a focus on pulmonary arterial hypertension and rare conditions. Its approved medicines, including Remodulin, Tyvaso, Orenitram, Adcirca, and Unituxin, treat PAH and pediatric neuroblastoma and are delivered by injections, inhalations, or oral tablets. The company also pursues regenerative medicine and xenotransplantation through its Lung Biotechnology PBC and Revivicor units to create bioengineered organs for transplant. It differentiates itself by combining drug development with organ engineering and by operating as a Public Benefit Corporation that balances profits with social and environmental goals, aiming to extend lives and increase access to transplantable organs.

Company Size

N/A

Company Stage

IPO

Headquarters

Silver Spring, Maryland

Founded

1996

Get referred to United Therapeutics Corporation

See people who can refer or advise you

Simplify's Take

What believers are saying

FDA accepted ralinepag NDA August 2026 and nebulized Tyvaso sNDA September 2026.
Q2 2026 net income rose to $333 million; buybacks retired 5.84% shares.
Phase 3 ADVANCE OUTCOMES and TETON showed improvement across PAH and IPF programs.

What critics are saying

Q2 2026 revenue fell 2%; Tyvaso sales dropped, exposing heavy product concentration.
Liquidia’s appeals and labeling fights can still blunt Treprostinil economics by 2027.
If ralinepag and IPF filings disappoint FDA, United Therapeutics remains a single-portfolio biotech.

What makes United Therapeutics Corporation unique

Martine Rothblatt built United Therapeutics around PAH drugs plus xenotransplantation, with three operating organ sites.
September 2026 Delaware ruling strengthened its treprostinil patent moat against Liquidia’s Yutrepia.
Stewartville’s August 12, 2026 DPF facility expands gene-edited pig organ production capacity.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
401(k) Retirement Plan
401(k) Company Match
Paid Time Off
Paid Holidays
Paid Vacation
Parental Leave

Company News

Yahoo Finance

Oct 16th, 2026

Two cash-rich stocks to watch, United Therapeutics and Core Natural Resources, and one to avoid

StockStory has named two cash-generating stocks to watch and one to avoid, arguing that strong cash flow alone does not guarantee good returns. It passes on Simply Good Foods, the maker of Atkins products. Revenue grew 5.2% annually over three years, sales are estimated to fall 9.9% in the next 12 months, and operating margin dropped 31.9 percentage points. The stock trades at $11.12, or 6.5x forward earnings. United Therapeutics, with a free cash flow margin of 34.6%, grew revenue 14.7% a year over five years and posts a 29.1% return on capital. It trades at $541.55, or 18.3x forward earnings. Core Natural Resources, a coal miner with a 6.1% free cash flow margin, grew revenue 15.6% annually over ten years to $4.27 billion. Its shares cost $89.05, or 20.7x forward earnings.

STAT

Oct 14th, 2026

FDA adcomm members' ties to industry under scrutiny.

FDA adcomm members' ties to industry under scrutiny. The FTC going after Martin Shkreli again, a study on GLP-1s and social outcomes, and more biotech news. Oct. 14, 2026 National Biotech Reporter Good morning. Yesterday, we got the devastating news that STAT's infectious disease correspondent, Helen Branswell, passed away. She was a reporter I always looked up to and was also an incredibly generous colleague. Please take the time to read this tribute to her. The need-to-know this morning. * Liquidia and United Therapeutics reached a settlement agreement that resolves their ongoing patent litigation over Liquidia's treatment for pulmonary arterial hypertension. New trial to test effect of GLP-1s on social outcomes. Researchers in Pittsburgh are launching a novel type of GLP-1 trial - testing not only if the drug will help people with addiction, but also if it will help reduce recidivism while improving other employment, health, and housing outcomes. The Center for Addiction Science, Policy and Research (CASPR), a non-profit organizing the effort, and the Allegheny County Department of Human Services are planning to launch the trial in early 2027. They will enroll up to 1,200 adults with alcohol use disorder, opioid use disorder, or both, who are also at high risk of criminal-justice involvement. Half will be randomly assigned to take Novo Nordisk's Wegovy, according to a press release issued yesterday. Your morning rundown of the science, politics, and money driving biotech today

Associated Press

Oct 13th, 2026

Liquidia to pay $380.7M to end all six lawsuits with United Therapeutics

Liquidia has settled all six lawsuits with United Therapeutics, ensuring patients with pulmonary arterial hypertension can keep using its inhaled drug YUTREPIA. The company will pay a net $380.7 million across 2026 and 2027. The deal follows a September 30, 2026, US District Court ruling that Liquidia infringed a United Therapeutics patent covering treatment of a related lung condition. Liquidia will not appeal and has asked to remove that indication from YUTREPIA's label. Payments include $175 million within 30 business days and $145.4 million in two instalments of $72.7 million, due by January 31, 2027, and April 30, 2027. Liquidia will also pay $60.3 million this month to parties with interests in related antitrust litigation. Liquidia reported preliminary third-quarter YUTREPIA net sales of $222.7 million and $396.1 million in cash as of September 30, 2026. It expects to fund the payments without new financing.

BioPharma Watch

Oct 13th, 2026

United Therapeutics presents new data at the CHEST 2026 Annual Meeting.

United Therapeutics presents new data at the CHEST 2026 Annual Meeting. Key Takeaway: United Therapeutics Corporation announced its participation in the CHEST 2026 Annual Meeting, where it will present two oral and five poster presentations. The event, hosted by the American College of Chest Physicians, will take place from October 18-21, 2026, in Phoenix, Arizona. The company aims to highlight its commercial and development portfolio. Market sentiment analysis. Positive factors. * Presentation of new data at a major conference. * Engagement with the medical community through sponsorship. * Diverse portfolio showcased through multiple presentations. BiopharmaWatch analysis. From its catalyst data and publicly available data · not financial advice Best trade, last catalyst 120-day peak, hindsight Typical move average across 6 past catalysts Lead asset NDA/BLA · Pulmonary Arterial Hypertension SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.-(BUSINESS WIRE)-United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that two oral and five poster presentations will be presented across its commercial and development portfolio at the CHEST 2026 Annual Meeting hosted by the American College of Chest Physicians taking place October 18-21, 2026, in Phoenix, Arizona. United Therapeutics will also sponsor and host Time to Look Closer: Emerging Data and Sc Frequently asked questions. What will United Therapeutics present at CHEST 2026? United Therapeutics will present two oral and five poster presentations. When is the CHEST 2026 Annual Meeting? The CHEST 2026 Annual Meeting will take place from October 18-21, 2026. Where is the CHEST 2026 Annual Meeting held? The meeting will be held in Phoenix, Arizona. Who hosts the CHEST 2026 Annual Meeting? The meeting is hosted by the American College of Chest Physicians.

BioSpace

Oct 2nd, 2026

Varda raises $251M to leverage gravity in space for drug production.

Varda raises $251M to leverage gravity in space for drug production. October 2, 2026 | Capitalizing on space's microgravity, the United Therapeutics-partnered Varda Space Industries aims to make medicines with better bioavailability and stability than Earth-produced molecules. Varda Space Industries has raised $251 million to manufacture medicines in space for patients on Earth. Lux Capital and Natural Capital co-led the series D round for Varda, valuing the company at $1.6 billion, Reuters reported on Wednesday. Varda, which was set up in 2021 by former SpaceX engineer Will Bruey and Founders Fund partner Delian Asparouhov, has now raised $598 million in total since its founding. The California-based startup launched its first mission in 2023 and has completed six successful reentries. Varda has booked 28 launches with SpaceX and other providers between 2027 and 2029, Reuters reported on Wednesday. The support reflects the belief that Varda is "the first and only company delivering a real cadence of launches and reentries," Shahin Farshchi, partner at Lux Capital, said in a prepared statement. Space's lower levels of gravity, which make objects seem weightless, influence crystal formation in ways that could affect drug properties such as stability and bioavailability. Evidence of the microgravity's effect on drug molecules has fueled decades of research. NASA sponsored a report on the topic in 1978, and Merck's space station research informed its subcutaneous Keytruda formulation. With the cost of sending a kilogram to orbit falling 96% from 1960 to 2025 and forecast to drop further through 2040, one barrier to commercially viable drug production in space is lowering. Varda is among the companies seeking to capitalize on the shift. The company launches its capsules into orbit aboard commercial rockets, such as SpaceX's Falcon 9. The capsules contain equipment for processing pharmaceuticals in orbit. After completing processing, the capsule separates from the orbital satellite, returns to Earth and is recovered for analysis. Other groups have shown that a small quantity of space-grown crystals can support multiple terrestrial production batches. In May, United Therapeutics partnered with Varda to develop improved formulations of treatments for rare lung indications. The pact supports the exploration of "how space-based manufacturing could contribute to significant improvements for rare pulmonary disease treatments," United Therapeutics CEO Martine Rothblatt said in a statement at the time. Varda and United Therapeutics have competition in the race to discover and make drugs in orbit. Space Microgravity Development (SpaceMD), part of the space and defense technology company Redwire, has given former Merck researcher Paul Reichert a strategic advisory role as it pursues orbital research and manufacturing. SpaceMD has signed a contract for a mission using Starfall, SpaceX's recently launched in-space manufacturing program. And Voyager Technologies operates research facilities aboard the International Space Station. The company's capacity, which supports a microgravity-enabled drug discovery pact with Space LiinTech, will be enhanced next year with a system for automated drug screening. Nick is a freelance writer who has been reporting on the global life sciences industry since 2008.

United Therapeutics Corporation

Senior Data Engineer

About the job